Pirozadil-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEPirozadilCat. No.: HY-100144CAS No.: 54110-25-7分式: CHNO分量: 527.52作靶點(diǎn): Others作通路: Others儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 62.5 mg/mL (118.48 mM; Need ultrasonic)H2O : 40% PEG30

2、0 5% Tween-80 45% salineSolubility: 2.08 mg/mL (3.94 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (3.94 mM); Suspended solution; Need ultrasonic3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oil1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.08 mg/mL (3.

3、94 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Pirozadil種降脂藥。體內(nèi)研究 Pirozadil is a hypolipidemic agent. Pirozadils effect on increasing cerebral blood flow is almost equal to thatof papaverine, less than that of nicardipine and much greater than that of the otherhypolipidemic/antiatherogenic drugs, nico

4、tinic acid and pyridinol carbamate. Pirozadil is also shown tosignificantly diminish vascular cerebral resistance to a much greater degree than nicotinic acid and pyridinolcarbamate 1.REFERENCES1. Roca J, et al. Effect of pirozadil on cerebral blood flow in anesthetized dogs. Methods Find Exp Clin Pharmacol. 1981 Nov-Dec;3(6):397-401.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;Fax